CN113577139A

CN113577139A - Application of plant composition in preparation of medicine for treating rhinitis

Info

Publication number: CN113577139A
Application number: CN202111043733.XA
Authority: CN
Inventors: 林瑞超; 董汛; 崔涛; 王京昆; 孙敏; 孙文强; 周云龙; 郭琰
Original assignee: Yunnan Baiyao Group Co Ltd
Current assignee: Yunnan Baiyao Group Co Ltd
Priority date: 2021-09-07
Filing date: 2021-09-07
Publication date: 2021-11-02

Abstract

The invention discloses an application of a plant composition in preparing a medicament for treating rhinitis, wherein the plant composition mainly comprises patchouli, rhizoma atractylodis, elsholtzia, folium artemisiae argyi, clove and mint, and the plant composition is used for preparing the medicament for treating the rhinitis and has obvious curative effects on various types of rhinitis such as acute rhinitis, chronic simple rhinitis, chronic hypertrophic rhinitis, rhinitis sicca, atrophic rhinitis, nasosinusitis and the like.

Description

Application of plant composition in preparation of medicine for treating rhinitis

Technical Field

The invention relates to the technical field of medicines, in particular to application of a plant composition in preparing a medicine for treating rhinitis.

Background

Rhinitis, an inflammatory disease of the nasal cavity, is inflammation of the mucous membrane of the nasal cavity caused by viruses, bacteria, allergens, various physicochemical factors and certain systemic diseases. The main pathological changes of rhinitis are congestion, swelling, exudation, hyperplasia, atrophy or necrosis of the nasal mucosa. China is one of the countries with high incidence of nasopharyngeal carcinoma, and 80% of nasopharyngeal carcinoma occurs in China all over the world, of which 90% is caused by the deterioration of rhinitis which is not cured after long-term treatment. Due to environmental pollution, the population of rhinitis patients is still increasing, and currently, more than 5 hundred million rhinitis patients are conservatively estimated worldwide. Chinese medicine for treating rhinitis mainly comprises antihistamine and nasal cortical hormone. These drugs can be used singly or in combination, but have limitations in effectiveness, antihistamines can relieve only rhinitis symptoms but not nasal congestion symptoms caused by rhinitis, nasal corticosteroids cannot quickly relieve symptoms, and they are not suitable for special groups because they may cause nasal irritation, bleeding, or other side effects.

In recent years, natural product drugs are considered as a new treatment strategy for preventing and treating inflammatory diseases, but in the research of the prior art, no detailed report on the preparation of the drug for treating rhinitis through medicinal plant compositions is available.

Disclosure of Invention

In view of the above, the invention provides an application of a plant composition in preparing a medicine for treating rhinitis, which can treat various types of rhinitis, such as acute rhinitis, chronic simple rhinitis, chronic hypertrophic rhinitis, rhinitis sicca, atrophic rhinitis, nasosinusitis and the like.

In order to achieve the purpose, the invention adopts the following technical scheme:

the application of a plant composition in preparing a medicine for treating rhinitis is characterized in that the plant composition mainly comprises patchouli, rhizoma atractylodis, elsholtzia, folium artemisiae argyi, clove and mint, and the plant composition is used for preparing the medicine for treating rhinitis.

Preferably, in the application of the plant composition in preparing the medicine for treating rhinitis, the plant composition also comprises natural borneol.

It is noted that the plant composition of the present invention is the pharmaceutical composition, the medicinal volatile oil or the medicinal aromatic water disclosed in the invention creation of application number "202010367580.3" entitled "an antibacterial and antiviral pharmaceutical composition and application thereof".

Preferably, in the application of the plant composition in preparing the medicine for treating rhinitis, the rhinitis comprises acute rhinitis, chronic simple rhinitis, chronic hypertrophic rhinitis, rhinitis sicca, atrophic rhinitis and nasosinusitis.

Preferably, in the application of the plant composition in preparing the medicine for treating rhinitis, the medicine for treating rhinitis is a spray.

Preferably, in the application of the plant composition in preparing the medicine for treating rhinitis, the medicine for treating rhinitis is a nasal drop.

Preferably, in the application of the plant composition in preparing the medicine for treating rhinitis, the medicine for treating rhinitis is a gel.

Preferably, in the application of the plant composition in preparing the medicine for treating rhinitis, the medicine for treating rhinitis is aerosol.

According to the technical scheme, compared with the prior art, the invention discloses the application of the plant composition in preparing the medicine for treating rhinitis, and the medicine has obvious curative effects on various types of rhinitis such as acute rhinitis, chronic simple rhinitis, chronic hypertrophic rhinitis, rhinitis sicca, atrophic rhinitis, nasosinusitis and the like.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1

An antibacterial and antiviral plant composition is in the form of spray, and is prepared by the following steps:

adding 10g natural borneol into 200ml medium chain triglyceride, heating and stirring at 50-60 ℃ to dissolve, cold cutting to room temperature, adding 20g patchouli oil, 20g atractylodes rhizome oil, 10g elsholtzia oil, 10g wormwood leaf oil, 5g clove oil and 5g peppermint oil, stirring uniformly, and subpackaging by using nasal administration spray bottles with 20ml of each to obtain the traditional Chinese medicine.

Example 2

An antibacterial and antiviral plant composition in the form of nasal drop is prepared by the following steps:

adding 10g of natural borneol into 200ml of medium-chain triglyceride, heating and stirring at 50-60 ℃ to dissolve, cold cutting to room temperature, adding 20g of patchouli oil, 20g of atractylodes rhizome oil, 10g of elsholtzia oil, 10g of folium artemisiae argyi oil, 5g of clove oil and 5g of peppermint oil, stirring uniformly, and subpackaging by using dropping bottles with 20ml of each to obtain the traditional Chinese medicine.

Example 3

An antibacterial and antiviral plant composition is in the form of aerosol, and is prepared by the following steps:

adding 10g natural Borneolum into 200ml medium chain triglyceride, heating and stirring at 50-60 deg.C to dissolve, cold cutting to room temperature, adding 20g oleum herba Pogostemonis, 20g rhizoma Atractylodis oil, 10g oleum Moslae, 10g oleum folium Artemisiae Argyi, 5g oleum Caryophylli, 5g peppermint oil, stirring, subpackaging each 20ml in aerosol aluminum can, capping, charging nitrogen gas to make internal pressure 0.8-1.0Mpa, and adding nasal cavity administration button.

Example 4

An antibacterial and antiviral plant composition is in the form of gel, and its preparation method comprises:

weighing 5g of natural borneol, 10g of patchouli oil, 10g of atractylodes rhizome oil, 5g of elsholtzia oil, 5g of blumea oil, 2.5g of clove oil and 2.5g of peppermint oil, mixing, and stirring to completely dissolve the natural borneol for later use.

Weighing 240g of hydroxypropyl-beta-cyclodextrin, adding into 100ml of purified water, heating to 60 ℃, stirring under magnetic stirring, dripping the mixed volatile oil into the solution, stirring for 3 hours under heat preservation, and freeze-drying to obtain the mixed volatile oil inclusion compound for later use.

92.5g of poloxamer P407 and 5.25g of poloxamer P188 are weighed out, placed in 362g of water and placed in an environment at 4 ℃ for 24h, and then the mixture is fully swelled. Adding the clathrate into the gel solution, stirring for dissolving, and packaging into spray bottle.

The spray obtained in example 1 was subjected to a pharmacodynamic study test:

1 Effect of sprays on acute rhinitis

1.1 Experimental methods

ICR mice are fed with the feed for 3 days in an adaptive manner, the weight of the ICR mice is 18-22 g, the ICR mice are half male and female, the ICR mice are randomly divided into 6 groups according to the weight, the groups are respectively a normal control group, a model control group, beclomethasone dipropionate 0.32mg/kg, a spray agent 50mg/kg group, a spray agent 100mg/kg group and a spray agent 200mg/kg group, and each group is 14 mice. Except for the normal control group, the nasal cavity of each group of mice is dripped with xylene 0.01mL each time for 2 times a day for 3 days continuously to prepare an acute rhinitis model, and the nasal cavity of the normal control group is dripped with physiological saline with the same amount. At the beginning of the 4d administration, 25. mu.L/corresponding drug was administered nasally, 2 times daily for 5 d.

1.2 index determination

1h after the last administration, each group of mice was bled from the eyeball, the EOS number in the blood was measured using an automatic hemocytometer, and the total IgE level in the serum was measured by radioimmunoassay. After sacrifice, the bulge of the nasal septum mucosa was removed, fixed with 10% neutral formaldehyde and the thickness of the nasal mucosa was measured by routine sectioning.

1.3 results of the experiment

1.3.1 Effect of spray on EOS in blood and IgE in serum of mouse acute rhinitis caused by xylene

TABLE 1 Effect of sprays on EOS and IgE in acute rhinitis of mice induced by xylene: (

n＝14)

Note: p <0.05, P <0.01 compared to model control.

According to the results shown in Table 1, it was found that: compared with a normal control group, the levels of EOS in blood and IgE in serum of the mice in the model control group are obviously increased (P < 0.01); compared with a model control group, the mice in each group of spraying agent can remarkably reduce EOS in blood and IgE level in serum (P <0.05 or P <0.01) after being administrated for 5 d.

1.3.2 Effect of spray on thickness of nasal mucosa of mouse acute rhinitis caused by xylene

TABLE 2 influence of spray on thickness of nasal mucosa of mouse acute rhinitis caused by xylene: (

n＝14)

Note: p <0.05, P <0.01 compared to model control.

According to the results shown in Table 2, it was found that: the nasal mucosa thickness of the model control mice was significantly reduced compared to the normal control group (P < 0.01); compared with a model control group, the thickness of the nasal mucosa can be increased (P <0.05 or P <0.01) when the spray is administrated to mice of each group for 5 days.

Under the experimental conditions and the designed dosage, the spray has obvious improvement effect on the acute rhinitis model mice.

2 Effect of sprays on Chronic rhinitis

2.1 Experimental methods

SD rats with weight of 180-220 g and half male and female, are adaptively fed for 3d, are randomly divided into 12 normal control groups and 70 model building groups, the model building groups are closed after being placed in a toxicant exposure box, and sodium sulfite reacts with concentrated sulfuric acid to generate SO₂Keeping the infection for 5min, 1 time/d, and taking 1 rest every 7d, starting im 0.75 mg/kg estradiol benzoate at 23d while the infection, and continuously injecting for 7d, 1 time/d. 60 rats successfully screened and modeled are randomly divided into 5 groups, namely a model control group, a beclomethasone dipropionate 0.18mg/kg group, a spray agent 10mg/kg group, a spray agent 20mg/kg group and a spray agent 40mg/kg group, wherein each group comprises 12 rats, 50 mu L of corresponding drugs are dripped into the nose of each group of rats, the dose is 2 times a day, and the dose time is 30 days. Normal control group and model control group were given an equal amount of physiological saline by nasal drip.

2.2 index determination

1h after the last administration, rats of each group were anesthetized with chloral hydrate, blood was taken from abdominal aorta, serum was partially separated, EOS number in blood was measured using an automatic hemocytometer, and total IgE level in serum was measured using radioimmunoassay. After sacrifice, the bulge of the nasal septum mucosa was removed, fixed with 10% neutral formaldehyde and the thickness of the nasal mucosa was measured on a routine slice.

2.3 results of the experiment

2.3.1 spray vs. SO₂Influence of EOS in blood and IgE in serum of rat chronic rhinitis

TABLE 3 spray vs SO₂The effects of EOS and IgE in chronic rhinitis of rats: (

n＝12)

Note: p <0.05, P <0.01 compared to model control.

According to the results shown in Table 3, it was found that: compared with a normal control group, the levels of EOS in blood and IgE in serum of rats in the model control group are obviously increased (P < 0.01); compared with a model control group, the rats in each group of spraying agent can obviously reduce EOS in blood and IgE level in serum (P <0.05 or P <0.01) after being administrated for 30 d.

2.3.2 spray vs. SO₂Influence of nasal mucosa thickness on chronic rhinitis of rats

TABLE 4 spray vs SO₂The influence of the thickness of nasal mucosa in chronic rhinitis in rats (

n＝14)

Note: p <0.05, P <0.01 compared to model control.

According to the results shown in Table 4, it was found that: the nasal mucosa thickness of the model control group rats is significantly reduced compared with the normal control group (P < 0.01); compared with a model control group, the nasal mucosa thickness (P <0.05 or P <0.01) can be remarkably increased by administering the spray to rats in each group for 30 d.

Under the experimental conditions and the designed dosage, the spray has obvious therapeutic action on the chronic rhinitis model rats.

3 Effect of sprays on atrophic rhinitis

3.1 Experimental methods

SD rats weighing 180-220 g, female rats and 3d rats are fed adaptively, the rats are randomly divided into a normal control group, a model control group, a viniane group of 0.15mg/kg, a spray agent group of 10mg/kg, a spray agent group of 20mg/kg and a spray agent group of 40mg/kg, and each group contains 12 rats. Except for the normal control group, rats in each group were subjected to bilateral ovariectomy after chloral hydrate anesthesia. After operation, the administration was started at 30 days, and each group of rats was administered with 50. mu.L of the corresponding drug by nasal drip 2 times a day for 30 days. Normal control group and model control group were given an equal amount of physiological saline by nasal drip.

3.2 index determination

3.3 results of the experiment

3.3.1 Effect of spray on EOS in blood and IgE in serum of rat model of atrophic rhinitis

TABLE 5 Effect of sprays on EOS and IgE in atrophic rhinitis model rats: (

n＝12)

Note: p <0.05, P <0.01 compared to model control.

According to the results shown in Table 5, it was found that: compared with a normal control group, the levels of EOS in blood and IgE in serum of rats in the model control group are obviously increased (P < 0.01); compared with a model control group, the rats in each group of spraying agent can obviously reduce EOS in blood and IgE level in serum (P <0.05 or P <0.01) after being administrated for 30 d.

3.3.2 Effect of sprays on thickness of nasal mucosa of atrophic rhinitis model rat

TABLE 6 influence of sprays on nasal mucosa thickness of atrophic rhinitis model rats: (

n＝14)

Note: p <0.05, P <0.01 compared to model control.

From the results shown in Table 6, it was found that: the nasal mucosa thickness of the model control group rats is significantly reduced compared with the normal control group (P < 0.01); compared with a model control group, the nasal mucosa thickness (P <0.05 or P <0.01) can be remarkably increased by administering the spray to rats in each group for 30 d.

Under the experimental condition and the designed dosage, the spray has obvious improvement effect on atrophic rhinitis model rats.

Clinical trials were conducted on the spray obtained in example 1 for the treatment of chronic rhinitis:

1.1 method: 50 patients were selected for hospital visits to chronic rhinitis conditions, of which 30 men, 20 women, 50 years of age maximum, 22 years of minimum, half a year to 3 years of disease.

1.2 using amount: the plant composition in the embodiment of the invention is used for treatment, 50 patients are randomly divided into 2 groups, the experiment group 1 is treated by the spray of the embodiment 1, the experiment group 2 is treated by the spray of the placebo of the normal saline, the application is carried out 3 times a day, 1 month is a treatment course, and the treatment effect is evaluated after one treatment course.

1.3 therapeutic effect judgment standard:

and (3) curing: the symptoms of nasal obstruction, nasal discharge, head distending pain and the like disappear, and the smell returns to normal. Special examination: the congestion and swelling of nasal mucosa are obviously relieved, and the middle and lower nasal turbinates are not obviously congested and swollen.

The method has the following advantages: the symptoms of nasal obstruction, nasal discharge, head distending pain and the like are relieved. Special examination: the congestion and swelling of nasal mucosa are reduced, the middle and lower nasal turbinates have no obvious congestion, and the swelling is reduced.

And (4) invalidation: the symptoms before and after treatment are unchanged.

As a result: the treatment results are shown in table 7.

TABLE 7 clinical trial results of the Chinese medicinal composition for treating chronic rhinitis

Test results	Cure (human)	Effective (human)	Invalid (human)	Total effective rate
					Experimental group 1	10	13	2	92％
Experimental group 2	3	5	17	32％

As can be seen from the table above, after clinical treatment, in experimental group 1, 10 cases (40%) were cured, 13 cases (52%) were effective, 1 case (8%) was not effective, and the total effective rate reached 92%; after the experiment group 2 is treated by the placebo, 3 cases (12%) are cured, 5 cases (20%) are effective, the total effective rate of the experiment group 2 is 32%, the clinical effect of the application is remarkable, and no serious adverse reactions such as allergy and the like exist in the treatment process, so that the plant composition is an effective medicament for treating chronic rhinitis.

Clinical cases of rhinitis:

patient 1: liu Zhi is a disease of women aged 30 years old with headache, fever, general malaise, nasal itching, frequent sneezing and diagnosed as acute rhinitis. After the patient uses the spray of the example 1 to treat the headache, the fever, the sneeze and the nose itch and relieve the symptoms after 3 days, the patient continues to use the spray of the example 1, the headache is avoided after the application for 7 days, and the patient is cured after the reexamination.

Patient 2: mr. Wang, frequent sneezing, nasal obstruction with heavy noise in dry and cold weather, nasal itching or foreign body sensation, frequent sneezing and burning sensation, and dry and congested mucous membrane in the front of nasal cavity, and sticky secretion or thin dry scab on the surface, can be used for diagnosing rhinitis sicca. The nasal drop of the embodiment 2 is used to relieve the symptoms on the same day, the effect is obvious after continuously using the nasal drop for more than 3 times per day for 5 days, the return visit symptoms basically disappear after 15 days, and the patients are satisfied.

Patient 3: for a certain period, male is 40 years old, the nose usually flows yellow nasal discharge for 2 years, occasionally becomes yellow and turbid like pus, the symptoms of the nasosinusitis are that the cold aggravates, the forehead is painful, the nasal obstruction is obstructed, the olfactory hypofunction is reduced, the forehead is slightly tenderness through diagnosis, the nasal ventilation function is poor, the tongue is red, the tongue coating is thin and yellow, and the pulse is deep and rapid. After 15 days using the aerosol formulation of example 3, the above symptoms disappeared.

Patient 4: wangzhi, male 35 years old often has symptoms of nasal obstruction, secretion incrustation, headache and the like, has a history of nasal drop medication, is diagnosed as drug rhinitis, and does not disappear after using the product for 15 days.

Clinical trials on a large number of patients have led to the following: the antibacterial and antiviral botanical composition of the present invention is not effective against all types of rhinitis due to the different symptoms and causes of each type of rhinitis, and as mentioned above, does not achieve the same therapeutic effect against drug-induced rhinitis as other types of rhinitis.

The embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other. For the scheme disclosed by the embodiment, the scheme corresponds to the method disclosed by the embodiment, so that the description is simple, and the relevant points can be referred to the method part for description.

The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. The application of a plant composition in preparing a medicine for treating rhinitis is characterized in that the plant composition is mainly composed of patchouli, rhizoma atractylodis, elsholtzia, folium artemisiae argyi, clove and mint and is used for preparing the medicine for treating rhinitis.

2. The use of a plant composition according to claim 1, in the preparation of a medicament for the treatment of rhinitis, wherein said plant composition further comprises natural borneol.

3. The use of a plant composition according to claim 1 or 2 in the manufacture of a medicament for the treatment of rhinitis, wherein said rhinitis comprises acute rhinitis, chronic simple rhinitis, chronic hypertrophic rhinitis, rhinitis sicca, atrophic rhinitis and sinusitis.

4. The use of a plant composition according to claim 3 in the preparation of a medicament for the treatment of rhinitis, wherein said medicament for the treatment of rhinitis is a spray.

5. The use of a plant composition according to claim 3 in the preparation of a medicament for the treatment of rhinitis, wherein said medicament for the treatment of rhinitis is a nasal drop.

6. The use of a plant composition in the preparation of a medicament for treating rhinitis according to claim 3, wherein the medicament for treating rhinitis is a gel.

7. The use of a plant composition according to claim 3 in the preparation of a medicament for the treatment of rhinitis, wherein said medicament for the treatment of rhinitis is an aerosol.